Patents by Inventor Sumihiro Nomura

Sumihiro Nomura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180282363
    Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
    Type: Application
    Filed: June 5, 2018
    Publication date: October 4, 2018
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Sumihiro NOMURA, Eiji KAWANISHI, Kiichiro UETA
  • Patent number: 9522931
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: December 20, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kenneth M. Wells, Ronald K. Russell, Xun Li, Shawn Branum, Derek A. Beauchamp, Sumihiro Nomura, Yosuke Matsumura
  • Publication number: 20160108078
    Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 21, 2016
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Sumihiro NOMURA, Eiji KAWANISHI, Kiichiro UETA
  • Patent number: 9024009
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: May 5, 2015
    Assignees: Janssen Pharmaceutica N.V., Mitsubishi Tanabe Pharma Corporation
    Inventors: Ahmed F. Abdel-Magid, Maureen Chislom, Steven Mehrman, Lorraine Scott, Kenneth M. Wells, Fan Zhang-Plasket, Sumihiro Nomura, Mitsuya Hongu, Yuichi Koga
  • Publication number: 20140296506
    Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
    Type: Application
    Filed: June 9, 2014
    Publication date: October 2, 2014
    Inventors: Sumihiro NOMURA, Eiji KAWANISHI, Kiichiro UETA
  • Publication number: 20140206859
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Application
    Filed: May 18, 2012
    Publication date: July 24, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Kenneth M. Wells, Xun Li, Shawn Branum, Sumihiro Nomura, Yosuke Matsumura
  • Publication number: 20140206858
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Application
    Filed: May 18, 2012
    Publication date: July 24, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Kenneth M. Wells, Ronald K. Russell, Xun Li, Shawn Branum, Derek A. Beauchamp, Sumihiro Nomura, Yosuke Matsumura
  • Patent number: 8785403
    Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
    Type: Grant
    Filed: June 12, 2012
    Date of Patent: July 22, 2014
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Sumihiro Nomura, Eiji Kawanishi, Kiichiro Ueta
  • Publication number: 20130289109
    Abstract: The present invention relates to a phenylalanine derivative of Formula (I) wherein X1 is a halogen atom, X2 is a halogen atom, Q is a CH2R— is a carboxyl group which may be esterified; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 3, 2013
    Publication date: October 31, 2013
    Inventors: Takayuki KAWAGUCHI, Sumihiro NOMURA, Mikiko TSUKIMOTO, Toshiyuki KUME, Ila SIRCAR
  • Patent number: 8513202
    Abstract: A novel crystal form of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: August 20, 2013
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Sumihiro Nomura, Eiji Kawanishi
  • Patent number: 8501809
    Abstract: The present invention relates to a phenylalanine derivative of Formula (I) wherein X1 is a halogen atom, X2 is a halogen atom, Q is a CH2R— is a carboxyl group which may be esterified; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: August 6, 2013
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Takayuki Kawaguchi, Sumihiro Nomura, Mikiko Tsukimoto, Toshiyuki Kume, Ila Sircar
  • Publication number: 20120258913
    Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
    Type: Application
    Filed: June 12, 2012
    Publication date: October 11, 2012
    Inventors: Sumihiro NOMURA, Eiji KAWANISHI, Kiichiro UETA
  • Patent number: 8222219
    Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: July 17, 2012
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Sumihiro Nomura, Eiji Kawanishi, Kiichiro Ueta
  • Patent number: 8202984
    Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: June 19, 2012
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Sumihiro Nomura, Eiji Kawanishi, Kiichiro Ueta
  • Publication number: 20120058941
    Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 8, 2012
    Inventors: Sumihiro NOMURA, Eiji Kawanishi, Kiichiro Ueta
  • Publication number: 20110212905
    Abstract: A novel crystal form of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.
    Type: Application
    Filed: May 9, 2011
    Publication date: September 1, 2011
    Inventors: Sumihiro Nomura, Eiji Kawanishi
  • Patent number: 7943582
    Abstract: A novel crystal form of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.
    Type: Grant
    Filed: December 3, 2007
    Date of Patent: May 17, 2011
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Sumihiro Nomura, Eiji Kawanishi
  • Patent number: 7943788
    Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.
    Type: Grant
    Filed: January 31, 2005
    Date of Patent: May 17, 2011
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Sumihiro Nomura, Eiji Kawanishi, Kiichiro Ueta
  • Publication number: 20110105424
    Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
    Type: Application
    Filed: January 13, 2011
    Publication date: May 5, 2011
    Inventors: Sumihiro NOMURA, Eiji Kawanishi, Kiichiro Ueta
  • Patent number: 7935674
    Abstract: Novel indole derivatives of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 is halogen, or alkyl, R2 is hydrogen, or halogen, Ar is phenyl, or thienyl, which may be substituted with halogen, alkyl, alkoxy, alkylthio, etc.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: May 3, 2011
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Sumihiro Nomura, Yasuo Yamamoto